The Spanish pharmaceutical group Insud Pharma will provide vial filling and packaging of AZD1222, the adenovirus vector COVID-19 vaccine candidate developed by the
Manufacturing will take place in the plant operated by the group's industrial unit, Chemo. AZD1222 is currently in clinical trials and approved for emergency supply in
With a track record spanning over 40 years, Insud Pharma is dedicated to research and development for medicines and APIs, with a total of six plants in
Universal Farma, a next-generation injectables plant inaugurated in 2017, has been selected to undertake the vial filling process and packaging for the vaccine. The plant currently has a team of professionals specialising in sterile injectables.
Insud Pharma is one of the pharmaceutical groups with the highest investment in R&D in our country, so much so that it received recognition as an Excellent company by the
In the words of
We are very happy to be able to manufacture the vaccine. We are proud to be able to contribute in such a decisive way to the solution of what has been one of the greatest problems in the health of our society. We are very satisfied that the vaccine can be manufactured in
Vaccine manufacturer for
In August this year, the President of
Insud Pharma, formerly Grupo Chemo, is a prestigious Spanish company which is widely respected in the pharmaceutical and health sector and has a track record spanning over 40 years. Early this year, the
With almost 6,000 employees in 40 countries, Insud Pharma's contribution to global public health is enormous, thanks to the medicines and APIs developed and manufactured at its three highly synergic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience).
Contact:
Tel: +34 91 771 15 00
Email: comunicacion@insudpharma.com
(C) 2021 Electronic News Publishing, source